Search - tctmd.com

Displaying 921 - 940 of 1462

Sort: Relevancy | Date

News Industry News

HeartWare Completes Enrollment In ENDURANCE2 Supplemental Destination Therapy Trial

August 10, 2015

News Daily News

Cardiac Rehab After Acute MI Still Underutilized in Older Patients

Yael L. Maxwell

August 07, 2015

News Daily News

RITA 3 Published: Routine Invasive Strategy in NSTE-ACS Loses Advantage at 10 Years

July 30, 2015

News Daily News

Study Suggests Patient Age of 90 Years or More Should Not Preclude TAVR

Todd Neale

July 27, 2015

News Industry News

HeartWare launches European trial for next-gen MVAD heart pump

July 20, 2015

News Daily News

Meta-analysis Confirms Safety of PCI without Surgical Backup

July 16, 2015

News Daily News

ADVANCE Published: Stroke Rate Diminishing as TAVR Evolves

Yael L. Maxwell

July 15, 2015

News Daily News

FDA Approves Heart Failure Drug That Comes With Survival Benefit

Todd Neale

July 13, 2015

News Daily News

Older Age Tied to Higher Risk of Recurrent Cerebral Ischemia in PFO Closure Patients

Yael L. Maxwell

July 08, 2015

News Daily News

Survival Benefit of CoreValve in High-Risk Patients Persists at 2 Years

July 07, 2015

News Industry News

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

July 07, 2015

News Daily News

Poor Mobility Strongly Predicts Mortality in TAVR Patients

Yael L. Maxwell

July 06, 2015

News Industry News

First Subject Enrolled in Veryan Medical's MIMICS-2 Study

July 01, 2015

Advertisement

HeartWare Completes Enrollment In ENDURANCE2 Supplemental Destination Therapy Trial

Cardiac Rehab After Acute MI Still Underutilized in Older Patients

RITA 3 Published: Routine Invasive Strategy in NSTE-ACS Loses Advantage at 10 Years

Study Suggests Patient Age of 90 Years or More Should Not Preclude TAVR

HeartWare launches European trial for next-gen MVAD heart pump

Meta-analysis Confirms Safety of PCI without Surgical Backup

ADVANCE Published: Stroke Rate Diminishing as TAVR Evolves

FDA Approves Heart Failure Drug That Comes With Survival Benefit

Older Age Tied to Higher Risk of Recurrent Cerebral Ischemia in PFO Closure Patients

Survival Benefit of CoreValve in High-Risk Patients Persists at 2 Years

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

Poor Mobility Strongly Predicts Mortality in TAVR Patients

First Subject Enrolled in Veryan Medical's MIMICS-2 Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content